RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics.

Sulzmaier FJ, Young-Robbins S, Jiang P, Geerts D, Prechtl AM, Matter ML, Kesari S, Ramos JW. RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. Oncotarget. 2016 Nov 29; 7(48):79869-79884.

View in: PubMed

subject areas

Adult
Animals
Brain Neoplasms
Cell Adhesion
Cell Line, Tumor
Cell Movement
Glioblastoma
Humans
Mice
Neoplasm Invasiveness
Ribosomal Protein S6 Kinases, 90-kDa

authors with profiles

Joe Ramos, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support